NASDAQ$FATE
Fate Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results and highlighted operational progress for the first quarter of 2022.
Fate Therapeutics reported $18.4 million in revenue for Q1 2022, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $641.7 million as of March 31, 2022.
- FT596+R enrollment is ongoing in single- and multi-dose, multi-cycle cohorts for R/R BCL.
- A clinical protocol for FT596+R-CHOP for first-line investigation will be submitted to the FDA in 2Q22.
- FT819 enrollment is ongoing in single- and multi-dose cohorts for R/R BCL in a landmark study of off-the-shelf, iPSC-derived CAR T-cell therapy.
- A multi-disciplinary RMAT meeting with the FDA is planned for mid-2022 for FT516.
Headline financials
Revenue & EPS history
Fate Therapeutics · Revenue · Quarterly
$18.4M
Revenue by segment
Fate Therapeutics · $18.4M total across 1 segment · Q1 2022
- Collaboration Revenue$18.4M+65.8%100.0%
Forward guidance
Fate Therapeutics is focused on advancing its iPSC-derived cell therapy programs and expects to provide clinical updates in the second half of 2022.
Tailwinds
- Preparing for submission to the FDA of a multi-disciplinary RMAT briefing package to inform pivotal study readiness in relapsed / refractory aggressive lymphoma.
- Preparing the FT596 plus R-CHOP clinical protocol to initiate investigation in first-line patients.
- Poised to treat the first solid tumor patient with FT536, a multi-antigen targeted CAR MICA/B NK cell product candidate.
- Initiated IND-enabling activities for two CAR NK cell product candidates under the collaboration with Janssen.
- Second GMP Manufacturing Facility Poised for Launch in 2H22.
Headwinds
- The Company’s product candidates may not demonstrate the requisite safety or efficacy to achieve regulatory approval or to warrant further development.
- Results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, may not be observed in ongoing or future studies involving these product candidates.
- There is a risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical studies.
- The Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons.
- The Company’s expenditures may exceed current expectations for a variety of reasons.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+19.0%
Q2 2016
Best reaction
-15.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | -22.8% | -8.5% | |
| Q4 2025 | +6.1% | -7.4% | -20.9% | |
| Q3 2025 | -2.1% | +6.1% | +16.2% | |
| Q1 2025 | -3.7% | +22.0% | +27.0% | |
| Q4 2024 | -1.6% | +2.2% | +20.7% | |
| Q3 2024 | -15.2% | -21.1% | -24.6% | |
| Q2 2024 | -1.8% | +2.1% | +12.3% | |
| Q1 2024 | +10.3% | +14.1% | -0.5% | |
| Q4 2023 | +7.2% | +11.2% | +5.5% | |
| Q3 2023 | -7.8% | -13.9% | -3.0% | |
| Q2 2023 | -4.2% | -13.0% | -30.4% | |
| Q1 2023 | +4.2% | -7.9% | -11.3% | |
| Q4 2022 | +1.3% | +1.7% | -11.8% | |
| Q3 2022 | -1.0% | -2.1% | +4.3% | |
| Q2 2022 | +6.3% | +11.5% | -12.8% | |
| Q1 2022 | -5.5% | -22.3% | -17.8% | |
| Q4 2021 | -1.5% | -7.0% | +14.1% | |
| Q3 2021 | +1.7% | +1.1% | -20.5% | |
| Q2 2021 | +14.8% | +15.0% | -12.3% | |
| Q1 2021 | -4.0% | -5.0% | -8.7% | |
| Q4 2020 | -9.6% | +1.2% | -24.4% | |
| Q3 2020 | -3.1% | +5.6% | +22.0% | |
| Q2 2020 | +2.5% | +10.4% | -4.6% | |
| Q1 2020 | -0.3% | -1.4% | +14.4% | |
| Q4 2019 | -3.3% | +0.9% | -30.8% | |
| Q3 2019 | -12.5% | -4.6% | -11.3% | |
| Q2 2019 | -3.8% | -2.9% | -6.0% | |
| Q1 2019 | -7.8% | -2.6% | -1.1% | |
| Q4 2018 | -3.1% | -0.1% | +12.0% | |
| Q3 2018 | +18.4% | +16.5% | +23.3% | |
| Q2 2018 | +15.6% | +17.6% | +28.6% | |
| Q1 2018 | -14.0% | -10.4% | +8.7% | |
| Q4 2017 | -1.6% | -0.8% | -20.8% | |
| Q3 2017 | -1.0% | +4.0% | -8.0% | |
| Q2 2017 | +6.7% | -3.4% | +44.6% | |
| Q1 2017 | +1.2% | -1.0% | -24.7% | |
| Q4 2016 | +5.5% | -3.4% | -10.4% | |
| Q3 2016 | +10.8% | +50.3% | +53.3% | |
| Q2 2016 | +19.0% | +21.3% | +20.9% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +15.9% | — | — | |
| Q2 2015 | -5.1% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2014 | +3.9% | — | — | |
| Q3 2013 | +1.9% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro